Chronic action of association of zidovudine, lamivudine and ritonavir on pregnant rats. A biologic assay


Autoria(s): WAGNER, A.; NAKAMURA, M. Uchiyama; SIMOES, R. S.; OLIVEIRA-FILHO, R. M.; FONTES, T. M. Pereira; CARVALHO, L. P. Fogarolli de; ESPIRIDIAO, S.; KULAY JR., L.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Purpose: To evaluate at term the effects of a highly active antiretroviral (HAAR) drug association administered during the entire period of rat pregnancy. Methods: Three groups (n = 10 each) of adult pregnant rats were treated with an oral solution of HAAR (Exp 1 = 10/5/20 mg/kg b.w.; Exp 2 = 30/15/60 mg/kg b.w.; Exp 3 = 90/45/180 mg/kg b.w.) from day ""0"" up to the 20th day of pregnancy. A fourth group served as a control. At term (20th day) the rats were killed under deep anesthesia and the number of implantations, resorptions, living fetuses, placentae and intrauterine deaths were recorded. Results: The highest HAAR doses caused lower maternal weight gain, lower litter weights, and lower placental weights compared to the control group. Conclusions: HAAR during the entire period of rat pregnancy can reduce maternal body weight gain and lower term placental weight.

Identificador

CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, v.38, n.1, p.28-32, 2011

0390-6663

http://producao.usp.br/handle/BDPI/28151

http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000288055100007&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord

Idioma(s)

eng

Publicador

I R O G CANADA, INC

Relação

Clinical and Experimental Obstetrics & Gynecology

Direitos

closedAccess

Copyright I R O G CANADA, INC

Palavras-Chave #Rat #Pregnancy #Zidovudine #Lamivudine #Ritonavir #RESISTANCE PROTEIN BCRP/ABCG2 #P-GLYCOPROTEIN #PLACENTA #INHIBITORS #EXPRESSION #HIV-1 #DRUGS #WOMEN #Obstetrics & Gynecology
Tipo

article

original article

publishedVersion